Related Experiment Videos
Malignant diseases after allogeneic bone marrow transplantation: an updated overview
G Socié1, M Henry-Amar, A Devergie
1Unité de Recherche sur la Biologie des Cellules Souches, Hôpital Saint Louis, Paris, France.
Nouvelle Revue Francaise D'Hematologie
|January 1, 1994
Summary
Late complications after allogeneic bone marrow transplantation include concerning malignant diseases. This review covers leukemias, lymphoma, and solid tumors as key risks in long-term survivors.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Allogeneic bone marrow transplantation (BMT) survivors face long-term risks.
- Malignant diseases are a significant clinical concern among late effects.
- Increased survival rates post-BMT highlight the importance of managing late complications.
Purpose of the Study:
- To review the incidence and characteristics of malignant diseases after allogeneic BMT.
- To consolidate data on leukemias, lymphomas, and solid tumors as late BMT complications.
- To inform clinical awareness and management strategies for long-term BMT recipients.
Main Methods:
- Literature review of reported cases and studies.
- Analysis of data on specific malignant complications.
- Synthesis of information on leukemias, lymphoma, and solid tumors post-allogeneic BMT.
Main Results:
- Leukemias, lymphoma, and solid tumors are recognized late complications.
- These malignancies represent a growing concern for patients surviving BMT.
- Data indicates a spectrum of malignant diseases can arise years after transplantation.
Conclusions:
- Malignant diseases are a critical area of focus for late effects after allogeneic BMT.
- Continued surveillance and research are necessary to understand and mitigate these risks.
- Awareness of these potential complications is vital for the long-term care of BMT patients.